Skip to content
Search
Close
Menu

Alice Chen, Ph.D.

  • About Us
  • Pipeline
  • Technology
  • News & Media
  • Partnership
  • Investors
  • Join Us
  • Contact Us
  • Term of Use
  • Privacy
Weixin
Linkedin-in Twitter Envelope

@2014-2023 Asieris Pharmaceuticals. All Rights Reserved.

Home
  • English
    • English
    • 中文
  • English
    • English
    • 中文
  •  English
    •       English
    •       中文
  • About Us
    • Our Mission
    • Our Values
    • Timeline
    • Management
    • ESG System
  • Pipeline
    • Urological Diseases
    • Gynecological Diseases
    • Other Diseases
    • Bladder Cancer
    • Precancerous Cervical Dysplasia
  • Technology
    • TIMN
    • PADD
    • FASTac
  • News
    • News
    • Awards
    • Media
    • PR Contact
  • Partnership
    • Collaboration
    • Contact us
  • Investors
  • Join Us
    • Openings
  • Contact
  • About Us
    • Our Mission
    • Our Values
    • Timeline
    • Management
    • ESG System
  • Pipeline
    • Urological Diseases
    • Gynecological Diseases
    • Other Diseases
    • Bladder Cancer
    • Precancerous Cervical Dysplasia
  • Technology
    • TIMN
    • PADD
    • FASTac
  • News
    • News
    • Awards
    • Media
    • PR Contact
  • Partnership
    • Collaboration
    • Contact us
  • Investors
  • Join Us
    • Openings
  • Contact
Alice Chen, Ph.D.

Vice President

Discovery Biology & Head of Translational Research

> Asieris Management Team
×
Alice Chen Phd.

Over 20 years of experience in the US pharmaceutical/biotech industry with a successful track record in drug discovery and translational research.

Served as a Research Fellow at 23andMe Inc., built up a biology team and led 23andMe’s internal and joint drug discovery effort with GSK in the oncology area; Under her leadership, a portfolio of immuno-oncology drug candidates has successfully advanced in 5 years, including 23andMe’s first and second compounds entering clinical trials; Led a biology team at NGM Bio-pharmaceuticals in California and discovered two compounds that entered into pre-clinical development; During her tenure at the Genomics Institute of the Novartis Research Foundation (GNF) in California, she led biology platforms and discovery projects, and made a significant contribution to the discovery of Siponimod, an approved drug for relapsing-remitting and secondary progressive multiple sclerosis.

Ph.D. in Neuroscience from Stanford University, BS in Biology from California Institute of Technology.

Published more than 20 scientific research papers with first-authored publications in prestigious journals such as Nature and Cell.

PrevYijun Deng, Ph.D.
Tie-Lin Wang, Ph.D.Next